WO2003004526A3 - Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments - Google Patents

Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments Download PDF

Info

Publication number
WO2003004526A3
WO2003004526A3 PCT/IB2002/003548 IB0203548W WO03004526A3 WO 2003004526 A3 WO2003004526 A3 WO 2003004526A3 IB 0203548 W IB0203548 W IB 0203548W WO 03004526 A3 WO03004526 A3 WO 03004526A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
apoptosis
viruses
resistance
reversion
Prior art date
Application number
PCT/IB2002/003548
Other languages
English (en)
Other versions
WO2003004526B1 (fr
WO2003004526A2 (fr
Inventor
Adam Telerman
Robert Amson
Marius Tuijnder
Original Assignee
Molecular Engines Lab
Adam Telerman
Robert Amson
Marius Tuijnder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engines Lab, Adam Telerman, Robert Amson, Marius Tuijnder filed Critical Molecular Engines Lab
Publication of WO2003004526A2 publication Critical patent/WO2003004526A2/fr
Publication of WO2003004526A3 publication Critical patent/WO2003004526A3/fr
Publication of WO2003004526B1 publication Critical patent/WO2003004526B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

La présente invention concerne notamment de nouvelles séquences impliquées dans les voies moléculaires de la suppression tumorale, la réversion tumorale, l'apoptose et/ou la résistance aux virus. Elle concerne également l'utilisation de ces séquences ou le traitement contre le cancer, maladies virales, maladies neurodégénératives ainsi qu'en matière de diagnostic ainsi que pour la mise en oeuvre de procédés de criblage de composés à tester. Cette invention a également pour objet des procédés de détection et/ou de dosage des séquences de l'invention ou de leurs produits d'expression dans un prélèvement biologique.
PCT/IB2002/003548 2001-06-20 2002-06-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments WO2003004526A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0108139A FR2826373A1 (fr) 2001-06-20 2001-06-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicamments
FR01/08139 2001-06-20

Publications (3)

Publication Number Publication Date
WO2003004526A2 WO2003004526A2 (fr) 2003-01-16
WO2003004526A3 true WO2003004526A3 (fr) 2003-06-05
WO2003004526B1 WO2003004526B1 (fr) 2003-07-24

Family

ID=8864571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003548 WO2003004526A2 (fr) 2001-06-20 2002-06-20 Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Country Status (2)

Country Link
FR (1) FR2826373A1 (fr)
WO (1) WO2003004526A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025177A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003087372A2 (fr) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Facteur de croissance derive d’hepatome et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014772A1 (fr) * 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
WO2001018542A2 (fr) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Compositions, trousses et methodes pour l'identification, l'analyse, la prevention et la therapie du cancer des ovaires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026245A2 (fr) * 1998-11-04 2000-05-11 Incyte Pharmaceuticals, Inc. Proteines de transport membranaire
WO2001023409A2 (fr) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 38 proteines secretees humaines
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020009724A1 (en) * 1999-12-08 2002-01-24 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014772A1 (fr) * 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
WO2001018542A2 (fr) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Compositions, trousses et methodes pour l'identification, l'analyse, la prevention et la therapie du cancer des ovaires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 30 July 1996 (1996-07-30), "Expressed sequence tag", XP002226777, retrieved from NCBI Database accession no. D20633 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "*DNA (human clone WO0118542_SEQID_4473 ovary tumor-associated protein cDNA", XP002226778, Database accession no. 226059-34-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002226776, Database accession no. 250054-08-1 *
DATABASE WPI Section Ch Week 199527, Derwent World Patents Index; Class B04, AN 1995-206931, XP002226779 *
DATABASE WPI Section Ch Week 200121, Derwent World Patents Index; Class B04, AN 2001-211428, XP002226780 *
ROPERCH JEAN-PIERRE ET AL: "SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: Identification of common effectors with p53 and p21Waf1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 14, 6 July 1999 (1999-07-06), pages 8070 - 8073, XP002182373, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003004526B1 (fr) 2003-07-24
WO2003004526A2 (fr) 2003-01-16
FR2826373A1 (fr) 2002-12-27

Similar Documents

Publication Publication Date Title
Swystun et al. Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO1998035693A3 (fr) Detection et modulation d'inhibiteurs de proteines d'apoptose (iap) et de polypeptides anti-apoptotiques apparentes (miap) permettant d'effectuer le diagnostic et le traitement de maladies proliferatives
WO2003004989A3 (fr) Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2003082210A3 (fr) Cibles, procedes et reactifs pour le diagnostic et le traitement de la schizophrenie
WO2004106495A3 (fr) Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2005059108A3 (fr) Profils d'expression geniques et procedes d'utilisation
WO2007058968A3 (fr) Profils d’expression genique et procedes d’utilisation
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
WO2004046332A3 (fr) Genes amplifies impliques dans un cancer
WO2005005661A3 (fr) Genes regules dans le cancer de l'ovaire utilises comme cibles pronostique et therapeutique
WO2008008983A3 (fr) Procédés et acides nucléiques pour des analyses de problèmes de la prolifération cellulaire
WO2003040369A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2002064731A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025176A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025175A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003004526A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003025177A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030312

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)